International Standards for Cord Blood Collection, Processing, Banking, Selection and Release - Australian Government


You must comply with this standard if you intend to use haematopoietic progenitor cells derived from cord blood for any commercial or scientific purpose.

Haematopoietic progenitor cells, otherwise known as stem cells, are used in research and approved experimental medical trials.

Please consult the Contact Officer for more information and to ascertain the level of compliance (if any) that may be required.

Service type

Code of Practice

A code of practice can be either a legal requirement or non-legal requirement. Legal codes of practice are defined as a result of legislation. Non-legal codes of practice are defined by industry regulators and bodies.

Act(s) name

Therapeutic Goods Act 1989 AG

Regulation(s) name

Therapeutic Goods Order No. 75 - Standard for Haematopoietic Progenitor Cells Derived from Cord Blood 2007 AG

Administering agency

Department of Health

Therapeutic Goods Administration

Contact details

Contact Email, Phone and Address Details for this service in simple two column table format, header then data.


Therapeutic Goods Administration

Department of Health

Operating address: 136 Narrabundah Lane
Australian Capital Territory 2609
Mailing address: TGA, PO Box 100
Australian Capital Territory 2606
Phone: 1800 020 653